DR.AGARWALS EYE HOSPITAL LTD.-$

Dr Agarwals Eye Hospital Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is effective from June 30, 2026, and is in accordance with the company's Code of Conduct for Prohibition of Insider Trading. The trading window is being closed in anticipation of the finalization and publication of the company's unaudited financial results for the quarter ending June 30, 2026. The window will reopen 48 hours after the announcement of these financial results, subject to Board of Directors' approval. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Dr. Agarwal’s Eye Hospital Limited has dispatched letters to equity shareholders and creditors, providing a direct web-link and QR code to access notices and documents for upcoming meetings. These meetings, directed by the Hon’ble National Company Law Tribunal, Chennai Bench, concern the proposed Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. The letters were sent to those whose email addresses are not registered with the Company/Registrar and Transfer Agents/Depository Participants/Depositories. Notices are also available on the BSE website.

Dr Agarwals Eye Hospital Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of ₹4 (40%) per equity share of ₹10 each, subject to shareholder approval. This is in addition to an interim dividend of ₹3 (30%) declared earlier, bringing the total dividend for FY26 to ₹7 (70%) per share. The Board meeting was held on May 20, 2026, where the results were approved.

Dr Agarwals Eye Hospital Ltd has declared a final dividend of ₹4 per equity share of ₹10 each for the financial year ended March 31, 2026. This is in addition to an interim dividend of ₹3, bringing the total dividend for the year to ₹7 per share. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of approval.

Dr Agarwals Eye Hospital Ltd. has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors, in its meeting held on May 20, 2026, approved the results and recommended a final dividend of ₹4 (40%) per equity share of ₹10 each, subject to member approval. This is in addition to an interim dividend of ₹3 (30%) already declared, bringing the total dividend for the year to ₹7 (70%) per share. The results are accompanied by an unmodified opinion from the Statutory Auditors, S.R. BATLIBOI & ASSOCIATES LLP.

Dr Agarwals Eye Hospital Ltd has scheduled a Board of Directors meeting on May 20, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. The board will also consider the recommendation of a Final Dividend for the Financial Year 2025-26. The trading window remains closed until 48 hours after the announcement of the financial results.

The Hon'ble NCLT, Chennai Bench, has approved the Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited (AEHL) and Dr. Agarwal's Health Care Limited (AHCL). The order, dated May 05, 2026, directs AEHL and AHCL to convene meetings of shareholders and creditors on July 02, 2026, to consider the proposed amalgamation. The certified copy of the order is awaited and will be made available on the AEHL website. The scheme is subject to necessary statutory and regulatory approvals.

Dr. Agarwal's Eye Hospital Limited's equity shares, currently listed and traded only on BSE, have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE) with effect from April 20, 2026, under the symbol "DRAGARWQ". This development is an exchange-led action initiated by NSE as per its trading regulations and "Permitted to Trade" frameworks. The company has not filed a formal listing application with NSE nor entered into a Listing Agreement for this purpose, and it continues to comply with all BSE listing obligations.

Dr Agarwals Eye Hospital Ltd. has announced the closure of its trading window for all designated persons and their immediate relatives, effective from March 31, 2026. This move comes in view of the finalization and publication of the audited financial results for the year ending March 31, 2026. The trading window is set to reopen after 48 hours from the announcement of the financial results, which will be duly approved by the Board of Directors. The closure is in accordance with the Company's Code of Conduct for Prohibition of Insider Trading.

Dr Agarwals Eye Hospital Ltd has received an observation letter from BSE Limited conveying 'no adverse observations' in relation to the Scheme of Amalgamation of Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. The Scheme is subject to the receipt of necessary statutory and regulatory approvals, including the approvals of the respective shareholders and creditors of the companies involved in the Scheme, and the jurisdictional National Company Law Tribunal.